Delayed Graft Function

Receiving a kidney transplant from a deceased donor who had dialysis before donation may be tied to a higher rate of delayed graft function, according to a published study.

Angion Biomedica Corp. has signed a licensing agreement with Vifor Pharma for the commercialization of ANG-3777, a drug shown to treat delayed graft function and cardiac surgery-associated AKI, according to a press release.

Kidneys from older donors showed no significant association with increased risk for delayed graft function, according to this study.

Use of the hepatocyte growth factor mimetic ANG-3777 showed long-term improvement in kidney function in patients who underwent transplantation but had signs of possible kidney injury after transplant.

WASHINGTON — ANG-3777, a hepatocyte growth factor mimetic, may be an effective treatment for delayed graft function in patients undergoing kidney transplant, according to study results presented at ASN Kidney Week.

At first glance, it is hard to say how the Advancing American Kidney Health initiative payment models will affect the operations or the finances of kidney transplant centers. While increasing the total number of kidney transplants performed is heavily incented in both the mandatory ESRD Treatment Choices and voluntary payment models, the financial carrots and sticks in this regard are directed only at general nephrologists and dialysis providers.

While African American patients have a higher prevalence of obesity and overweight status and continue to experience disparities in access to kidney transplantation, BMI does not appear to be a barrier for transplant referral.